Heptares Therapeutics Articles

Oxford BioThera and Boehringer Ingelheim collaborate; Milestone for Heptares

29 April 2013

MorphoSys and Heptares collaborate to develop antibody therapeutics targeting GPCRs

13 February 2013

Cubist partners with Heptares on new medicines targeting GPCRs; provides 2012 business update

8 January 2013

Shire signs $190 million deal for preclinical CNS drug

21 March 2012

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront

31 May 2011

Shire gets exclusive option for Heptares A2A program for CNS diseases

10 May 2011

UK’s Heptares in CNS deal with Takeda worth potential £65 million

12 April 2011

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end